Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WeChat-based reeducation to improve H. pylori eradication with bismuth quadruple therapy
ChiCTR2100048004Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of proton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: H. pylori eradication rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
proton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100048004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048004.